주식/증권
📈 긍정적
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
요약
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.